The overexpression of the TKs is associatedwith angiogenesis and synovial hyperplasia in the RA.160 Tyrosine kinase is a highly studied therapeutictarget for various inflammatory diseases.161 There are multiple inhibitors reported against TKs, such as fostamatinib(spleenTK/STK inhibitor), tofacitinib (a Janus kinase inhibitor),ruxolitinib, evobrutinib, and BMS-986142, but only the first two arebeing utilized as oral treatments for RA.162,163 Further research is needed to understand how TKs modulate the immuneresponse in RA, as their specific mechanism remains unknown. This evidence concerns the gene CDC42 and rheumatoid arthritis.